NGENHealthcare · BiotechnologyNGEN Stock Forecast: NervGen Pharma Corp. Price Predictions for 2026-2027
The 7 Wall Street analysts covering NervGen Pharma Corp. hold a median 12-month price target of $10 — +539.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 14 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
NGEN stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores NervGen Pharma Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (69): Smaller than most of the companies we track.
Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
NGEN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NGEN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +539.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 July 2026 | HC Wainwright & Co. | Maintains | Buy | $18 → $15 |
| 13 July 2026 | Leerink Partners | Initiates | Outperform | $10 |
| 27 Apr 2026 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NGEN appears on the weeks it earns a place.
NGEN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, NervGen Pharma Corp. returned −52.9% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
NGEN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
NervGen Pharma Corp. (NGEN) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −2.6×
- Price / sales
- —
- Price / book
- 13.7×
- EV / EBITDA
- −2.5×
Cheaper than 87% of US stocks
Cheaper than 7% of US stocks
Cheaper than 75% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −757.5%
- Return on assets
- −37.7%
- Dividend yield
- 0.0%
Higher than 2% of US stocks
Higher than 11% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
NervGen Pharma Corp. (NGEN) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
NervGen Pharma Corp. has a market value of $168.3M and an enterprise value of $57.3M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$62.0M.
Free cash flow in the twelve months to 30 June 2026: −$25.6M.
Trailing P/E: −2.6×; forward P/E: −4.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%.
NervGen Pharma Corp. employs 9 people.
Data provided by Twelve Data
NGEN vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own NervGen Pharma Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about NGEN stock
What is the NGEN stock price forecast for 2026-2027?
The 7 Wall Street analysts covering NervGen Pharma Corp. have a median 12-month price target of $10, with estimates ranging from $10 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NGEN stock a buy right now?
Of the 7 analysts covering NervGen Pharma Corp., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NervGen Pharma Corp. 23 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NGEN?
As at 14 Oct 2026, NervGen Pharma Corp. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (69 of 100).
Will NGEN stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts implies +539.0% from the last close, and Ticker Nerd's factor model ranks NervGen Pharma Corp. 23 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NGEN stock forecast for 2030?
No analyst covering NervGen Pharma Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $10 over the next 12 months.
How has NGEN stock performed over the past year?
NervGen Pharma Corp. returned -52.9% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
What does NervGen Pharma Corp. do?
NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing neuroreparative therapies designed to support nervous system repair after injury or disease.
About NervGen Pharma Corp.
NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing neuroreparative therapies designed to support nervous system repair after injury or disease. The company’s lead program, NVG-291, is being studied in spinal cord injury and other neurologic conditions, while its pipeline also includes additional candidates in preclinical development. NervGen’s work centers on addressing biological barriers that limit neural recovery, with applications across neurotrauma and neurodegenerative disease areas. The company’s research and development efforts are aimed at advancing treatments for conditions such as spinal cord injury, stroke, multiple sclerosis, and amyotrophic lateral sclerosis, positioning NervGen Pharma Corp. as a specialized participant in the emerging neuroreparative medicine segment of biotechnology.
CEO Dr. Adam H. Rogers M.D. · 9 employees · Canada · https://www.nervgen.com